ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1786

Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE

Vibeke Strand1, Annette Diehl2, Jared Christensen2, Joseph Wajdula2, Sudhakar Sridharan3 and Paul J Healey2, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Pfizer Inc, New York City, NY, 3PPD Inc, Rockville, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: clinical trials, fatigue and quality of life, IL-6, Lupus

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The
10 mg dose of PF-04236921 showed evidence of efficacy in
a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported
outcomes (PROs) from this trial are presented.

Methods: Subjects
with active SLE (SLEDAI-2K ≥6; BILAG A in ≥1 organ system or B in
≥2 organ systems) received PF-04236921 10, 50, or
200 mg, or placebo, SC every 8 weeks; the 200 mg dose was prematurely
discontinued due to safety findings. The primary endpoint was the SLE Responder
Index-4 (SRI-4) at Week 24. Secondary endpoints included Short Form-36
(SF-36), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and
European Quality of Life (EQ-5D) visual analog scale (VAS). These PROs were
analyzed by least squares (LS) mean changes from baseline at Week 24, without
imputation. An enriched population of subjects with one or more indicators of
high baseline disease activity (SLEDAI-2K ≥10, detectable anti-dsDNA
levels, prednisone >7.5 mg/day, and/or low complement) was defined for a
post-hoc analysis.

Results:
Baseline
SF-36 physical (PCS) and mental component summary (MCS), and domain scores were
lower than age- and gender-matched US norms and other RCTs in SLE,3
indicating that subjects enrolled in this trial were more impacted by their
disease. In the enriched population, statistically significant improvements in
SF-36 PCS scores were reported with 10 mg versus placebo, and physical
functioning, bodily pain, general health and vitality domain scores approached statistical
significance; all of which exceeded minimum clinically important differences
(MCID; Table 1). Numerical improvements in FACIT-Fatigue and EQ-5D VAS with 10
mg exceeded MCID in both total and enriched populations. Improvements reported
with 50 mg differed from placebo, but statistical significance was not achieved
in either population (Table 1).

Conclusion:
These results demonstrate statistically significant and clinically important improvements
in SF-36 PCS scores for the 10 mg dose in the enriched population, supported by
changes >MCID in 4 of 8 SF-36 domains, FACIT-Fatigue, and EQ-5D VAS. These
results are consistent with the primary efficacy data and indicate greater
benefit following treatment with PF-04236921 10 mg in the enriched population.

ClinicalTrials.gov identifier, NCT01405196

1. Wallace D et al. ACR Annual Meeting 2014

2. Smolen J et al. EULAR Annual Meeting 2015

3. Strand V et al. Ann Rheum Dis 2014;73:838-844

Strand et al_ACR 2015 abstract_final draft_23Jun2015


Disclosure: V. Strand, AbbVie, Alder, Amgen, Anthera, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Genentech, GSK, Janssen, Merck Serono, Novartis, Pfizer Inc, Sanofi-Aventis, and UCB Pharma, 2; A. Diehl, Pfizer Inc, 3; J. Christensen, Pfizer Inc, 1,Pfizer Inc, 3; J. Wajdula, Pfizer Inc, 1,Pfizer Inc, 5; S. Sridharan, Pfizer Inc, 9; P. J. Healey, Pfizer Inc, 1,Pfizer Inc, 5.

To cite this abstract in AMA style:

Strand V, Diehl A, Christensen J, Wajdula J, Sridharan S, Healey PJ. Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/improvements-in-health-related-quality-of-life-and-fatigue-following-administration-of-an-il-6-monoclonal-antibody-pf-04236921-in-an-enriched-population-of-subjects-with-active-sle/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvements-in-health-related-quality-of-life-and-fatigue-following-administration-of-an-il-6-monoclonal-antibody-pf-04236921-in-an-enriched-population-of-subjects-with-active-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.